Xtant Medical (NYSEAMERICAN:XTNT) Shares Pass Above 200 Day Moving Average of $0.00

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $1.18. Xtant Medical shares last traded at $1.14, with a volume of 87,368 shares traded.

Wall Street Analysts Forecast Growth

Separately, BTIG Research began coverage on shares of Xtant Medical in a research report on Tuesday, December 5th. They issued a “buy” rating and a $2.00 price objective for the company.

Xtant Medical Stock Up 3.5 %

The company has a market capitalization of $153.53 million, a price-to-earnings ratio of 114.00 and a beta of 0.20. The company has a current ratio of 2.92, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26.

Institutional Trading of Xtant Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in XTNT. Vanguard Group Inc. raised its holdings in shares of Xtant Medical by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 1,499,993 shares of the medical device company’s stock valued at $1,695,000 after acquiring an additional 14,653 shares during the period. AMH Equity Ltd purchased a new position in Xtant Medical during the third quarter valued at approximately $653,000. AWM Investment Company Inc. purchased a new position in Xtant Medical during the third quarter valued at approximately $516,000. Bridgeway Capital Management LLC grew its position in Xtant Medical by 118.7% during the fourth quarter. Bridgeway Capital Management LLC now owns 368,500 shares of the medical device company’s stock valued at $416,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Citadel Advisors LLC grew its position in Xtant Medical by 88.5% during the fourth quarter. Citadel Advisors LLC now owns 59,866 shares of the medical device company’s stock valued at $68,000 after purchasing an additional 28,105 shares in the last quarter. 63.44% of the stock is currently owned by institutional investors.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix.